Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 3/2018

01-07-2018 | Editorial

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

Authors: Rajan Kapoor, Rajiv Kumar

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2018

Login to get access

Excerpt

Thomas Hodgkin, in 1832, as the ‘Inspector of the Dead and Curator of the Museum’ at the medical school of Guys hospital published a paper on “On Some Morbid Appearances of the Absorbant Glands and the Spleen”, what later on Samuel Wilks in the true spirit of peer recognition named as ‘Hodgkin’s disease’ in 1865 [1]. Hodgkin tried cascarilla, soda and iodine to treat his initial 07 patients with obvious lack of success and who went on to become the subjects of autopsy. The long journey in the management of lymphomas to the current day success story has been phenomenal. We are beginning to look at a chemotherapy and radiotherapy free treatment protocol as the cobweb of signal transduction pathways becomes clearer and we are able to unravel the ways to use the targeted therapies in various combinations to achieve the goal of ‘cure’. …
Literature
1.
go back to reference Bonnadonna G (2000) Historical review of Hodgkin’s disease. Br J Haematol 110:504–511CrossRef Bonnadonna G (2000) Historical review of Hodgkin’s disease. Br J Haematol 110:504–511CrossRef
2.
go back to reference Bonnadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259CrossRef Bonnadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259CrossRef
3.
go back to reference Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed
4.
go back to reference Stephens DM (2017) Brentuximab: Is it time for for a new “B” in ABVD? Blood 130:1281–128CrossRef Stephens DM (2017) Brentuximab: Is it time for for a new “B” in ABVD? Blood 130:1281–128CrossRef
5.
go back to reference Kakroo A, Bafna A, Gogia A, Vora A, Pathak A, Korula A et al (2018) Management of Lymphomas: consensus document 2018 by an Indian Expert Group. Indian J Hematol Blood Transfus (Online First) Kakroo A, Bafna A, Gogia A, Vora A, Pathak A, Korula A et al (2018) Management of Lymphomas: consensus document 2018 by an Indian Expert Group. Indian J Hematol Blood Transfus (Online First)
Metadata
Title
Lymphoma in ‘India’ at the Dawn of Targeted Therapies
Authors
Rajan Kapoor
Rajiv Kumar
Publication date
01-07-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-0973-6

Other articles of this Issue 3/2018

Indian Journal of Hematology and Blood Transfusion 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine